ArticleScientific reports2026
Association of anemia with long-term renal prognosis in autosomal dominant polycystic kidney disease using time-series analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Attribute-based cross-classification reveals sex- and age-specific prognostic impact of anemia in ADPKD.Clinical and experimental nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
We enrolled 553 patients with autosomal dominant polycystic kidney disease (ADPKD) to investigate the association between hemoglobin (Hb) levels and kidney outcomes. Renal outcome was defined as a 50% reduction in estimated glomerular filtration rate or the initiation of renal replacement therapy. Survival analyses and logistic regression were used to generate time-series McFadden’s pseudo-R-squared (pseudo-R²) values as a goodness-of-fit index to compare the relative contribution of Hb cut-offs over follow-up time, and the mean pseudo-R² values from the first to the 17th year (1–17Y mean) were calculated to summarize long-term patterns. Multivariable Cox analyses indicated that lower Hb was independently associated with kidney disease progression (per 1 g/dL decrease in Hb, P = 0.0016). The highest 1–17Y mean values were observed for Hb < 12.0 g/dL for the entire cohort (1–17Y mean: 0.1128), Hb < 13 g/dL for men (1–17Y mean: 0.1838), and Hb < 12 g/dL for women (1–17Y mean: 0.1191). These findings suggest that Hb thresholds around 12.0 g/dL overall—and sex-specific thresholds of 13 g/dL in men and 12 g/dL in women—showed relatively stronger and more persistent associations with renal outcomes over follow-up time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.